Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease

Kok Pin Ng, Tharick A. Pascoal, Sulantha Mathotaarachchi, Yiong Huak Chan, Lai Jiang, Joseph Therriault, Andréa Lessa Benedet, Monica Shin, Nagaendran Kandiah, Celia M.t. Greenwood, Pedro Rosa‐Neto, Serge GauthierResearch 2020 · DOI

Introduction

Alzheimer’s disease (AD) is traditionally defined by cognitive impairment, but biological changes begin decades before memory loss. Recent research suggests that neuropsychiatric symptoms (NPS)—such as irritability, depression, and anxiety—may be among the earliest non-cognitive manifestations of the disease. This study investigates whether these behavioral changes can predict the biological onset of AD by examining brain metabolism in individuals genetically destined to develop the condition.

The Challenge of Early Detection

A major hurdle in AD research is identifying reliable markers during the "preclinical" stage. While NPS are common in late-stage dementia, their role in early stages has been debated: are they a reaction to cognitive decline, or a direct result of early brain injury? To isolate the effects of AD pathology from general aging, researchers studied Dominantly Inherited Alzheimer’s Disease (DIAD). Because DIAD is caused by specific genetic mutations with full penetrance, researchers can study young, cognitively healthy individuals who will eventually develop the disease.

Study Methodology

The researchers analyzed longitudinal data from 221 cognitively intact participants (119 mutation carriers and 102 non-carriers) from the Dominantly Inherited Alzheimer’s Network (DIAN).

  • NPS Assessment: The Neuropsychiatric Inventory-Questionnaire (NPI-Q) was used to screen for 12 behavioral domains.
  • Metabolic Imaging: [18F]FDG-PET scans measured glucose metabolism, serving as a proxy for neuronal activity and health.
  • Estimated Years of Onset (EYO): This metric represents the number of years until a participant is expected to show symptoms, based on their parent's age of onset.
  • Analysis: Mixed-effects regression models evaluated how the interaction between NPS severity and EYO influenced brain metabolism.

Key Insights: Behavior as a Biomarker

The study revealed that behavioral changes are statistically linked to the rate of metabolic decline in the brain. Crucially, this association was only found in mutation carriers, suggesting that NPS are a specific feature of the Alzheimer’s biological process rather than a general aging effect.

Exploratory factor analysis identified a specific cluster of symptoms—agitation, disinhibition, irritability, and depression—as the primary drivers of metabolic decline. These behaviors appear to signal the beginning of a metabolic "crash" in key brain networks.

Key Results: Mapping the Metabolic Decline

The interaction of higher NPS scores and a shorter time to expected onset (EYO) was associated with a more rapid decline in both global and regional brain glucose uptake.

Voxel-wise analysis and regional metabolic decline associated with the interaction of NPI-Q and EYO.

Voxel-based analysis identified significant metabolic "hotspots" in the posterior cingulate cortex (PCC), ventromedial prefrontal cortex (vmPFC), and the right insula. These regions are part of the Default Mode Network (DMN) and the Salience Network (SN), which are critical for emotion regulation and are typically the first areas affected by AD pathology.

Conclusion and Future Directions

The findings support the emerging framework that NPS are early clinical indicators of neuronal injury in AD. In cognitively healthy individuals at risk for AD, monitoring behavioral shifts could provide a non-invasive window into the brain's metabolic health.

While DIAD provides a clear model for AD progression, future research is needed to validate these findings in the more common sporadic (late-onset) AD population. Additionally, using more sensitive tools like the Mild Behavioral Impairment Checklist (MBI-C) may help detect even subtler behavioral changes in the earliest stages of the disease.

Summary updated

Abstract

Abstract Background: Neuropsychiatric symptoms (NPS) are increasingly recognized as early non-cognitive manifestations in the Alzheimer’s disease (AD) continuum. However, the role of NPS as an early marker of pathophysiological progression in AD remains unclear. Dominantly inherited AD (DIAD) mutation carriers are young individuals who are destined to develop AD in future due to the full penetrance of the genetic mutation. Hence, the study of DIAD mutation carriers enables the evaluation of the associations between pure AD pathophysiology and metabolic correlates of NPS without the confounding effects of co-existing pathologies. In this longitudinal study, we aimed to identify regional brain metabolic dysfunctions associated with NPS in cognitively intact DIAD mutation carriers. Methods: We stratified 221 cognitively intact participants from the Dominantly Inherited Alzheimer’s Network according to their mutation carrier status. The interactions of NPS measured by the Neuropsychiatric Inventory-Questionnaire (NPI-Q), age, and estimated years of onset (EYO) as a function of metabolism measured by [ 18 F]flurodeoxyglucose ([ 18 F]FDG) positron emission tomography, were evaluated by the mixed-effects regression model with family-level random effects in DIAD mutation carriers and non-carriers. Exploratory factor analysis was performed to identify the neuropsychiatric subsyndromes in DIAD mutation carriers using the NPI-Q sub-components. Then the interactions of specific neuropsychiatric subsyndromes with EYO on metabolism were evaluated with the mixed-effects regression model. Results: A total of 119 mutation carriers and 102 non-carriers were studied. The interaction of higher NPI-Q and shorter EYO was associated with more rapid declines of global and regional [18F]FDG uptake in the posterior cingulate and ventromedial prefrontal cortices, the bilateral parietal lobes and the right insula in DIAD mutation carriers. The neuropsychiatric subsyndromes of agitation, disinhibition, irritability and depression interacted with the EYO to drive the [18F]FDG uptake decline in the DIAD mutation carriers. The interaction of NPI and EYO was not associated with [18F]FDG uptake in DIAD mutation non-carriers. Conclusions: The NPS in cognitively intact DIAD mutation carriers may be a clinical indicator of subsequent metabolic decline in brain networks vulnerable to AD, which supports the emerging conceptual framework that NPS represent early manifestations of neuronal injury in AD. Further studies using different methodological approaches to identify NPS in preclinical AD are needed to validate our findings.
BibTeX
@inproceedings{ng2020neuropsychiatric,
  author = {Kok Pin Ng and Tharick A. Pascoal and Sulantha Mathotaarachchi and Yiong Huak Chan and Lai Jiang and Joseph Therriault and Andréa Lessa Benedet and Monica Shin and Nagaendran Kandiah and Celia M.T. Greenwood and Pedro Rosa‐Neto and Serge Gauthier},
  title = {{Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-53396/v4},
}
Figure